Drug Interactions between gabapentin and Truqap
This report displays the potential drug interactions for the following 2 drugs:
- gabapentin
- Truqap (capivasertib)
Interactions between your drugs
No interactions were found between gabapentin and Truqap. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
gabapentin
A total of 270 drugs are known to interact with gabapentin.
- Gabapentin is in the drug class gamma-aminobutyric acid analogs.
-
Gabapentin is used to treat the following conditions:
- Alcohol Use Disorder (off-label)
- Alcohol Withdrawal (off-label)
- Anxiety (off-label)
- Back Pain
- Benign Essential Tremor (off-label)
- Bipolar Disorder (off-label)
- Burning Mouth Syndrome (off-label)
- Carpal Tunnel Syndrome (off-label)
- Chronic Kidney Disease-Associated Pruritus (off-label)
- Chronic Pain
- Cluster-Tic Syndrome (off-label)
- Cough (off-label)
- Diabetic Peripheral Neuropathy (off-label)
- Epilepsy
- Erythromelalgia (off-label)
- Fibromyalgia (off-label)
- Hiccups (off-label)
- Hot Flashes (off-label)
- Hyperhidrosis (off-label)
- Insomnia (off-label)
- Lhermitte's Sign (off-label)
- Migraine (off-label)
- Nausea/Vomiting, Chemotherapy Induced (off-label)
- Neuropathic Pain (off-label)
- Occipital Neuralgia (off-label)
- Pain (off-label)
- Periodic Limb Movement Disorder (off-label)
- Peripheral Neuropathy (off-label)
- Postherpetic Neuralgia
- Postmenopausal Symptoms (off-label)
- Primary Orthostatic Tremor (off-label)
- Pruritus (off-label)
- Pudendal Neuralgia (off-label)
- Reflex Sympathetic Dystrophy Syndrome (off-label)
- Restless Legs Syndrome (off-label)
- Seizures
- Small Fiber Neuropathy (off-label)
- Spondylolisthesis (off-label)
- Syringomyelia (off-label)
- Transverse Myelitis (off-label)
- Trigeminal Neuralgia (off-label)
- Vulvodynia (off-label)
Truqap
A total of 398 drugs are known to interact with Truqap.
- Truqap is in the drug class multikinase inhibitors.
- Truqap is used to treat Breast Cancer.
Drug and food interactions
capivasertib food
Applies to: Truqap (capivasertib)
GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations of capivasertib, which is primarily metabolized by CYP450 3A4. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. Inhibition of hepatic CYP450 3A4 may also contribute. The interaction has not been studied with grapefruit juice but has been studied with other CYP450 3A4 inhibitors. Based on clinical studies and model-informed approaches, concomitant use with the potent CYP450 3A4 inhibitor itraconazole is predicted to increase capivasertib systemic exposure (AUC) by up to 1.7-fold and peak plasma concentration (Cmax) by up to 1.4-fold. Coadministration with the moderate CYP450 3A4 inhibitors erythromycin and verapamil is predicted to increase the AUC and Cmax of capivasertib by up to 1.5-fold 1.3-fold, respectively. In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition. Increased exposure to capivasertib may increase the risk of adverse effects such as diarrhea, cutaneous adverse reactions, decreased lymphocytes, decreased hemoglobin, hyperglycemia, nausea, and fatigue.
MANAGEMENT: It may be advisable for patients to avoid the consumption of grapefruit, grapefruit juice, or supplements that contain grapefruit during treatment with capivasertib.
References (1)
- (2023) "Product Information. Truqap (capivasertib)." Astra-Zeneca Pharmaceuticals
gabapentin food
Applies to: gabapentin
GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.
MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.
References (4)
- Warrington SJ, Ankier SI, Turner P (1986) "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology, 15, p. 31-7
- Gilman AG, eds., Nies AS, Rall TW, Taylor P (1990) "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.
- (2012) "Product Information. Fycompa (perampanel)." Eisai Inc
- (2015) "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.